Novo Nordisk A/S Class B Return on Equity

Novo Nordisk A/S Class B (NONOF) currently reports a ROE of 51.96%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Novo Nordisk A/S Class B's ROE history and peer comparisons.

Novo Nordisk A/S Class B's ROE of 51.96% is higher than the Healthcare sector average of -75.84%. That is roughly 168.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Novo Nordisk A/S Class B's current 51.96% should be judged against Healthcare norms (sector average: -75.84%) and against NONOF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 51.96%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Novo Nordisk A/S Class B, and consider following NONOF for alerts when major investors trade the stock.

Novo Nordisk A/S Class B is classified in the Healthcare sector. On ROE, it currently shows 51.96% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NONOF with unrelated industries.